Journal of Clinical Rheumatology
A double-blind, randomised, placebo-controlled clinical trial investigating the safety and efficacy of Arthrem® in patients with osteoarthritis of the hip or knee was conducted at Dunedin Hospital. The results have been recently published in the medical journal Clinical Rheumatology. Results of the trial were extremely positive with the group of patients taking Arthrem® (at the recommended dose of 1 capsule twice daily) showing statistically significant improvements in pain and physical function over 12 weeks. Arthrem® at this dose was also well tolerated with no treatment-related side effects.
Journal of Inflammation Research
Our independent laboratory research helps explain why Arthrem® may support stiff joints. A paper published in The Journal of Inflammation Research shows that the primary ingredient of Arthrem® has potent anti-inflammatory activity in vitro. Concentrations as low as 0.05% completely inhibited production of the inflammatory mediator tumour necrosis factor-alpha. The extract was also a strong inhibitor of the cyclooxygenase (COX) inflammatory marker, prostaglandin E2.